Aberdeen Group Reduces Stake in Vertex Pharmaceuticals

Institutional investor lowers holdings in biotech firm by 16.8% in Q4 2025

Apr. 3, 2026 at 7:05am

Got story updates? Submit your updates here. ›

An extreme close-up of gleaming, industrial banking equipment and mechanisms, conveying the secure, physical nature of financial institutions and investments without using any literal currency or charts.The complex financial machinery behind institutional investment decisions reflects the power and influence of major players like Aberdeen Group.Boston Today

Aberdeen Group plc, a major institutional investor, lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 16.8% in the fourth quarter of 2025, according to a recent 13F filing with the Securities & Exchange Commission. The firm now owns 262,057 shares of the pharmaceutical company's stock, valued at $118.81 million.

Why it matters

Vertex Pharmaceuticals is a leading biotech firm focused on developing innovative treatments for serious diseases like cystic fibrosis. Changes in institutional ownership of the company's stock can signal shifts in investor sentiment and market expectations around the firm's future performance.

The details

In its latest 13F filing, Aberdeen Group reported selling 52,832 shares of Vertex Pharmaceuticals during the fourth quarter of 2025. The firm now owns approximately 0.10% of Vertex's outstanding stock. Several other major institutional investors, including Vanguard Group, Capital Research Global Investors, and Alliancebernstein, also hold significant stakes in the pharmaceutical company.

  • Aberdeen Group filed its 13F report for Q4 2025 on April 3, 2026.
  • The firm lowered its Vertex Pharmaceuticals holdings during the three-month period ending December 31, 2025.

The players

Aberdeen Group plc

A major institutional investor and asset management firm based in the United Kingdom.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Aberdeen Group's Vertex Pharmaceuticals holdings suggests a potential shift in investor sentiment around the biotech firm, though the reasons behind the move are not entirely clear. Analysts will likely monitor Vertex's performance and any further changes in institutional ownership as the company continues to advance its pipeline of innovative treatments.